Skip to main content
Delfa

← Trials/Trial dossier/NCT00901498

CompletedPhase 1

Relative Bioavailability Study of Four Experimental Formulations for Alzheimer's Disease

A Bioavailability Study of Four Experimental BMS-708163 Formulations Relative to Solubilized Capsule Formulation in Healthy Young Male Subjects

Asset

Avagacestat

Listed sites

1

Recruiting sites

-

Enrollment

36

actual

Study population

Alzheimer’s disease

Key I/E criteria

•Age 18-45•Male

Primary endpoint

•Bioavailability of 4 experimental formulations relative to the current

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

Org study IDCN156-004
NCT IDNCT00901498

Timeline

Milestones

Study start2009-05 (month precision)
Study first posted2009-05-13estimated
Primary completion2009-07actual (month precision)
Study completion2009-07actual (month precision)
Last update posted2011-01-07estimated

Assets

Drug assets

Avagacestat

Study populations

Who this study enrolls

Alzheimer’s disease

Eligibility

Who can enroll

Minimum age18 Years
Maximum age45 Years
SexMale
Healthy volunteersAccepted

Inclusion criteria

•Young healthy male subjects

Exclusion criteria

•Women

Endpoints (5)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Safety / tolerability / PK
4
Other (unclassified)
1

Safety / tolerability / PK

4 endpoints
Secondary/protocol endpoint

Safety: Adverse Events

Time frame:Day 1, up to 3 weeks

event count, event

Secondary/protocol endpoint

Safety: Vital Signs

Time frame:Screening, Day 1 and Day 4 of each period

descriptive

Secondary/protocol endpoint

Safety: ECGs

Time frame:Screening, Day 1 of each period, up to 3 weeks

descriptive

Secondary/protocol endpoint

Safety: Clinical Lab Tests

Time frame:Screening, Day -1 of each period, Day 1, up to 3 weeks

descriptive

Other (unclassified)

1 endpoint
Primary/protocol endpoint/low confidence

To assess the bioavailability of 4 experimental formulations relative to the current reference formulation

Time frame:Day 1, up to 3 weeks

descriptive

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 21, 2026
Endpoint classificationDelfa ADRD endpoint taxonomy
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 21, 2026 snapshot.